LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Home・Aandelen Lijst・Boston Scientific Corp.

Boston Scientific Corp.

Gesloten

SectorGezondheidszorg

57.61 1.02

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

57.41

Max

57.67

Belangrijke statistieken
By Trading Economics
Inkomsten	669M 1.3B
Verkoop	-83M 5.2B
K/W Sectorgemiddelde	23.398 49.701
EPS	0.8
Winstmarge	25.774
Werknemers	59,000
EBITDA	116M 1.1B

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+51.66% upside

Dividenden
By Dow Jones
Volgende Winsten	29 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-7.5B 83B
Vorige openingsprijs	56.59
Vorige sluitingsprijs	57.61

Nieuwssentiment

By Acuity

26%

74%

59 / 345 Rangschikking in Healthcare

Boston Scientific Corp. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mei 2026, 11:04 UTC

Acquisities, Fusies, Overnames

Boston Scientific Buys 34% Stake in MiRus for $1.5 Billion

22 apr 2026, 11:22 UTC

Winsten

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adjusted EPS View

4 feb 2026, 16:14 UTC

Winsten

Belangrijke Marktbewegers

Boston Scientific Plunges on Disappointing 1Q Outlook Despite 4Q Earnings Beat

4 feb 2026, 12:13 UTC

Winsten

Boston Scientific Sees More Growth after Earnings, Sales Rise

6 mei 2026, 20:15 UTC

Winsten

Penumbra Not Be Providing Fincl Guidance Due to Pending Acquisition by Boston Scientific >PEN

6 mei 2026, 20:07 UTC

Winsten

Penumbra 1Q Rev $374.8M >PEN

6 mei 2026, 20:07 UTC

Winsten

Penumbra 1Q EPS 82c >PEN

22 apr 2026, 11:07 UTC

Winsten

Boston Scientific 1Q Net Grows Sharply, Company Cuts 2026 Adj EPS View

22 apr 2026, 10:32 UTC

Winsten

Boston Scientific Now Sees 2026 Reported Sales Up 7%-8.5%, Organic Sales Up 6.5%-8% >BSX

22 apr 2026, 10:31 UTC

Winsten

Boston Scientific Sees 2Q Reported Sales Up 5.5%-7.5%, Organic Sales Up 5%-7% >BSX

22 apr 2026, 10:30 UTC

Winsten

Boston Scientific 1Q Organic Sales Up 9.4% >BSX

22 apr 2026, 10:30 UTC

Winsten

Boston Scientific 1Q Adj EPS 80c >BSX

22 apr 2026, 10:30 UTC

Winsten

Boston Scientific 1Q EPS 90c >BSX

22 apr 2026, 10:30 UTC

Winsten

Boston Scientific 1Q Sales $5.2B >BSX

22 apr 2026, 10:30 UTC

Winsten

Boston Scientific Sees 2Q Adj EPS 82c-Adj EPS 84c >BSX

22 apr 2026, 10:30 UTC

Winsten

Boston Scientific Sees FY Adj EPS $3.34-Adj EPS $3.41 >BSX

30 mrt 2026, 15:34 UTC

Marktinformatie

Boston Scientific Faces Some Slowing Growth Trends -- Market Talk

4 feb 2026, 21:41 UTC

Winsten

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 19:38 UTC

Winsten

These Stocks Are Today's Movers: AMD, AbbVie, Boston Scientific, Eli Lilly, MP Materials, Super Micro, Palantir, and More -- Barrons.com

4 feb 2026, 17:32 UTC

Winsten

These Stocks Are Today's Movers: AMD, AbbVie, Eli Lilly, Boston Scientific, MP Materials, Super Micro, Silicon Labs, Uber, and More -- Barrons.com

4 feb 2026, 15:30 UTC

Winsten

Boston Scientific Earnings Beat Estimates. It's the Worst Stock in the S&P 500 Today. -- Barrons.com

4 feb 2026, 15:29 UTC

Winsten

These Stocks Are Today's Movers: AMD, Eli Lilly, AbbVie, Uber, Super Micro, Enphase, Boston Scientific, and More -- Barrons.com

4 feb 2026, 14:06 UTC

Winsten

Boston Scientific Profit, Sales Rise but Issues Soft Guidance -- Update

4 feb 2026, 13:58 UTC

Winsten

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 feb 2026, 13:12 UTC

Winsten

Boston Scientific Earnings Beat Expectations. Why the Stock Is Down Sharply. -- Barrons.com

4 feb 2026, 11:32 UTC

Winsten

Boston Scientific Sees 2026 Sales Up 10.5%-11.5%, Organic Sales Up 10%-11% >BSX

4 feb 2026, 11:31 UTC

Winsten

Boston Scientific Sees 1Q Sales Up 10.5%-12%, Organic Sales Up 8.5%-10% >BSX

4 feb 2026, 11:30 UTC

Winsten

Boston Scientific 4Q Organic Sales Up 12.7% >BSX

4 feb 2026, 11:30 UTC

Winsten

Boston Scientific Sees 2026 Adj EPS $3.43-Adj EPS $3.49 >BSX

4 feb 2026, 11:30 UTC

Winsten

Boston Scientific Sees 1Q Adj EPS 78c-Adj EPS 80c >BSX

Peer Vergelijking

Prijswijziging

Boston Scientific Corp. Prognose

Koersdoel

By TipRanks

51.66% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 87.63 USD 51.66%

Hoogste 118 USD

Laagste 68 USD

Gebaseerd op 27 Wall Street-analisten die 12-maands prijsdoelen bieden voor Boston Scientific Corp. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

27 ratings

Buy

Hold

Sell

Gebaseerd op 27 analisten die aandelenratings hebben gegeven aan Boston Scientific Corp. - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

59 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.